Tempus Brings New Possibilities in the Fight Against Cancer to Chicago

Home / Tempus Brings New Possibilities in the Fight Against Cancer to Chicago

Cancer has long been the single most dangerous affliction facing humanity at large. Those that are fortunate enough to survive their battle against cancer still suffer the debilitating symptoms brought upon by the disease itself and the very treatments designed to combat it. Though devastating, cancer is completely an issue that can be solved with the right tools and resources available to the right doctors and specialist.

The doctors of Chicago’s University of Chicago gained such a tool in their fight to better treat those in their care. Tempus, the creation of Groupon founder Eric Lefkofsky, has partnered with the medical establishment and has provided the oncology departments with access to their state of the art data collection and analyzation programs. Tempus will aid doctors by collecting and analyzing data collected from thousands of breast cancer patients to help researchers and doctors find any similarities between the data that can be used to improve treatments.The disease as dangerous as it is, has very little collected data on the patients that battle the disease.

Dr. Olufunmilayo Olopade, Dean for Global Health at the University of Chicago spoke about the lack of usable data in a statement made to press, “This forces too many physicians to make treatment decisions without the benefit of highly specific genetic information that could help them make better informed and precisely targeted decisions.” She continued, “We are excited to partner with Tempus on this initiative and eager to support its efforts to build the largest clinically annotated molecular data set in breast cancer.”The partnership comes on the heels of a string of new partnerships between the tech start-up and other establishments who are embroiled in the fight to end cancer. The start-up that sprung into the scene earlier last year has quickly gone from unknown start-up to leading the charge among tech start-ups in the fight to end cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *